StreetAlpha
Eloxx Pharmaceuticals, Inc. · Earnings

ELOX Earnings Results and History

Latest: Q3 2026From SEC 8-K, 10-Q and 10-K filingsNext report: Feb 12, 2027

Eloxx Pharmaceuticals, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← ELOX stock page

Q3 2026 result
Beat on EPS
  • EPS−$0.49 vs −$0.58 est +15.0%
  • Revenue–

Filed ยท Press release

Key takeaways

from the press release
  • First two patients dosed in the Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome. Topline data expected mid-2027.
  • IND cleared for the Phase 2 EXPRESS study in nonsense mutation ADPKD. First patient expected to be dosed in Q3 2027.
3 more takeaways with a free account.Create free account

Year by year

fiscal years, from 10-K filings
Year endedRevenueGrowthOp marginNet incomeEPS
Dec 31, 2025$0−100.0%–−$6M−$0.49
Dec 31, 2024$6.4M–−38.8%−$3.1M−$0.84
Dec 31, 2023$0––−$17.1M−$6.63
Dec 31, 2022–––−$36.1M−$16.65
Dec 31, 2021–––−$66.7M−$38.15

Filings and dates

SEC EDGAR
  • Feb 12, 2027Next earnings reportexpected
  • Nov 16, 2026Earnings release, Q3 20268-K Press release
  • Nov 16, 2026Quarterly report10-Q All filings

Also see ELOX institutional ownership and the earnings calendar.

ELOX earnings FAQ

What were ELOX's latest earnings?

For Q3 2026 Eloxx Pharmaceuticals, Inc. reported, GAAP EPS of -$0.49. The results were filed with the SEC on Nov 16, 2026.

When is ELOX's next earnings date?

Eloxx Pharmaceuticals, Inc. is expected to report on Feb 12, 2027. Dates can move until the company confirms them.

Where do these numbers come from?

Results, guidance and financials come from Eloxx Pharmaceuticals, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.